Today's Date: June 3, 2023
UNice Celebrates LGBTQ Pride Month   •   FNKO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Funko, Inc. Investors with Substantial Losses Have Opp   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of LivePerson, Inc. (LPSN) Investors   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5   •   The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve   •   Statement from Minister Hutchings on progress in support of rural Canadians   •   SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and   •   HESAI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Hesai   •   Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice   •   Rapid Dose Announces Proposed Private Placement Financing   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors   •   Hilton brings back exclusive pop-up hotel experience 'Hilton on the Green' to the 2023 RBC Canadian Open   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   ETHNIC CONFLICTS IN NIGERIA: UNMASKING THE PUPPET MASTERS   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   BURGERFI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bu
Bookmark and Share

Clinicians Identify Buprenorphine “Spiking” In JAMA Psychiatry Study Supported by Millennium Health Researchers

SAN DIEGO , March 22 /Businesswire/ - A JAMA Psychiatry study, led by Jarratt D. Pytell, MD, MHS, Department of Medicine, University of Colorado School of Medicine, and co-authored by Brendan Saloner, PhD, Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, and Millennium Health researchers calls attention to factors associated with patients who have urine drug test (UDT) samples suggestive of buprenorphine “ADD-IN” (commonly referred to as “spiking”). Buprenorphine is used to treat pain and opioid use disorder (OUD). Spiking a urine sample represents intentional addition of buprenorphine tablet or residue directly into the urine to mimic adherence with prescribed buprenorphine.

This cross-sectional study of 507,735 urine specimens from 58,476 patients with OUD collected between January 1, 2017 and April 30, 2022 found:

  • For patients prescribed buprenorphine, a norbuprenorphine to buprenorphine urinary ratio of <0.02 identified samples suggestive of spiking
  • 7.6% of patients had evidence suggestive of spiking
  • Specimens suggestive of spiking were more likely to be positive for nonprescribed opioids
  • Specimens obtained from primary care clinics were more likely be suggestive of spiking

According to lead researcher Jarratt D. Pytell, MD, “I anticipate a much-needed increase in the number of people gaining access to buprenorphine therapy. The results are tremendously timely, given they come on the heels of the elimination of the X waiver. This study highlights some of the complexities of prescribing buprenorphine. New prescribers of buprenorphine will need to learn how to conduct the increasingly complex initiation of treatment and then gauge whether it is successful or not. Spiking suggests that treatment is not working – especially in patients continuing illicit drug use. Detecting spiking allows clinicians to adjust or intensify the treatment plan.”

“At Millennium Health we have been tracking the enormity of the drug use crisis. This study suggests that spiking is an important patient safety issue, and it is not uncommon,” said study co-author Eric Dawson, PharmD, VP of Clinical Affairs, Millennium Health. “Detection of spiking requires definitive drug testing. Immunoassay based, point-of-care tests cannot detect spiking because they are generally incapable of quantitative analysis and differentiating buprenorphine from norbuprenorphine.”

The JAMA article can be accessed here.

About Millennium Health

Millennium Health is an accredited specialty laboratory providing medication monitoring via definitive urine and oral fluid drug tests to support improved clinical decision-making as part of treatment for millions of Americans with chronic pain, mental illness, substance use disorders, and other health conditions. Drug testing is used to obtain objective information about patients’ recent use of prescription medications and/or illicit drugs and helps monitor the effectiveness of treatment plans. We also conduct real-time tracking of emerging drug use trends to help researchers, public health officials, and policymakers address the significant increase in drug overdose deaths.

STORY TAGS: United States, North America, Pharmaceutical, Science, Health, Research, California, Product/Service,


White House Live Stream
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News